Research Topics
Genomes and Genes | Bryan P SchneiderSummaryAffiliation: Indiana University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Triple-negative breast cancer: risk factors to potential targetsBryan P Schneider
Indiana University, Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, USA
Clin Cancer Res 14:8010-8. 2008..This CCR focus article will review the current state of the art on triple-negative breast cancer...- A large, consistent plasma proteomics data set from prospectively collected breast cancer patient and healthy volunteer samplesCatherine P Riley
Bindley Bioscience Center, Purdue University, West Lafayette, IN, USA
J Transl Med 9:80. 2011..Variability of plasma sample collection and of proteomics technology platforms has been detrimental to generation of large proteomic profile datasets from human biospecimens... - The role of vascular endothelial growth factor genetic variability in cancerBryan P Schneider
Indiana University, Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, USA
Clin Cancer Res 15:5297-302. 2009..If validated, these finding could help direct which subgroup of patients should receive bevacizumab... - Anti-VEGF therapy as adjuvant therapy: clouds on the horizon?Bryan P Schneider
Indiana University Simon Cancer Center, Indianapolis, IN 46220, USA
Breast Cancer Res 11:303. 2009..How concerning are these preclinical studies, and should they affect our willingness to explore anti-VEGF therapy in the adjuvant setting?.. - Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100Bryan P Schneider
Indiana University School of Medicine, Indianapolis, IN, USA
J Clin Oncol 26:4672-8. 2008..Therefore, we evaluated the association of VEGF genotype with efficacy and toxicity in E2100, a phase III study comparing paclitaxel versus paclitaxel plus bevacizumab as initial chemotherapy for metastatic breast cancer... - Exploratory study evaluating the association of polymorphisms of angiogenesis genes with hot flashesBryan P Schneider
Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
Breast Cancer Res Treat 116:543-9. 2009..We evaluated the association between germline polymorphisms in genes important to angiogenesis and subjective reporting of hot flashes... - Association of polymorphisms of angiogenesis genes with breast cancerBryan P Schneider
Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
Breast Cancer Res Treat 111:157-63. 2008..We report our preliminary data evaluating the association of polymorphisms from seven genes known to influence angiogenesis with the likelihood of having breast cancer... - Angiogenesis of breast cancerBryan P Schneider
Division of Hematology-Oncology, Indiana University, 535 Barnhill Dr, RT-473 Indianapolis, IN 46202, USA
J Clin Oncol 23:1782-90. 2005 - Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodesBryan P Schneider
Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA
Breast Cancer Res Treat 96:209-15. 2006..There was concordance between the genotypes of germline DNA obtained from uninvolved lymph nodes and those determined in tumor samples, implying that the host angiogenic genotype imprints the tumor genotype... - A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumorsKenneth A Kesler
Department of Surgery, Cardiothoracic Division, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
Ann Thorac Surg 85:371-8. 2008..We reviewed our institution's 25-year experience in the cisplatin era to determine surgical risks and predictors of survival after surgery for PMNSGCT... - Drug insight: VEGF as a therapeutic target for breast cancerBryan P Schneider
Indiana University, Division of Hematology Oncology, Indiana University School of Medicine, Indianapolis, IN, USA
Nat Clin Pract Oncol 4:181-9. 2007..This Review will focus on the current state of therapeutics designed to inhibit this angiogenic process in breast cancer... - Resequencing of the vascular endothelial growth factor promoter reveals haplotype structure and functional diversityMilan Radovich
Department of Medicine, Division of Hematology, Indiana University School of Medicine, Indianapolis, IN, USA
Angiogenesis 13:211-8. 2010..Haplotypes containing SNPs previously reported to be associated with increased survival with the use of bevacizumab are high-expressing haplotypes, thus lending putative functional evidence to the prior clinical finding... - Is the blood-brain barrier relevant in metastatic germ cell tumor?Jose M Azar
Department of Medicine, Division of Hematology and Oncology, Indiana University, Indianapolis, IN, USA
Int J Radiat Oncol Biol Phys 69:163-6. 2007..We propose to document that the BBB is also relevant in germ cell tumors despite their dramatic chemosensitivity... - Outcome of patients with residual germ cell or non-germ cell malignancy after resection of primary mediastinal nonseminomatous germ cell cancerBryan P Schneider
Divisions of Hematology-Oncology, Indiana Cancer Pavilion, Indianapolis, IN 46202-5289, USA
J Clin Oncol 22:1195-200. 2004..In this poor-risk patient population, surgical resection of persistent cancer, even in the presence of elevated STMs, can still achieve long-term survival... - Compliance differences between patients with breast cancer in university and county hospitalsIan K Komenaka
Department of Surgery, Indiana University, IN 46202, USA
Clin Breast Cancer 10:385-91. 2010..Compliance with recommended breast cancer treatments outside the context of a clinical trial differs from that in study populations. The purpose of this study was to examine differences in compliance of breast cancer treatments... - Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group studyBryan P Schneider
Division of Hematology-Oncology, Indiana University Medical Center and Walther Cancer Institute, Indianapolis, IN 46202, USA
Oncology 65:218-23. 2003..CONCLUSIONS: The combination of gemcitabine and docetaxel is a well-tolerated regimen with clinical efficacy. The ultimate role of this combination versus single-agent gemcitabine can only be determined by a randomized phase III trial...